|
2025-03-20 |
2025-03-19 |
VP
Vente planifiée
|
Tak Paul Peter
Chief Executive Officer
Administrateur exécutif
|
400
-0.2%
9,00
3 601 USD
|
400
-0.2%
|
9,00
|
3 601 USD
|
|
|
2025-03-20 |
2025-03-18 |
VP
Vente planifiée
|
Nichols William Garrett
Chief Medical Officer
Dirigeant
|
45 316
-46.3%
8,76
396 995 USD
|
45 316
-46.3%
|
8,76
|
396 995 USD
|
|
|
2025-03-20 |
2025-03-18 |
VP
Vente planifiée
|
Barone Francesca
Chief Scientific Officer
Dirigeant
|
32 146
-25.0%
8,76
281 673 USD
|
32 146
-25.0%
|
8,76
|
281 673 USD
|
|
|
2025-03-20 |
2025-03-18 |
VP
Vente planifiée
|
Tak Paul Peter
Chief Executive Officer
Administrateur exécutif
|
25 772
-10.2%
8,77
226 023 USD
|
25 772
-10.2%
|
8,77
|
226 023 USD
|
|
|
2025-03-19 |
2025-03-17 |
VP
Vente planifiée
|
Tyagarajan Seshu
Chief Technology Officer
Dirigeant
|
31 278
-26.8%
8,82
275 947 USD
|
31 278
-26.8%
|
8,82
|
275 947 USD
|
|
|
2025-03-19 |
2025-03-17 |
VP
Vente planifiée
|
Schoch Charles
See Remarks
Dirigeant
|
5 000
-11.6%
8,83
44 169 USD
|
5 000
-11.6%
|
8,83
|
44 169 USD
|
|
|
2025-01-17 |
2025-01-15 |
V
Vente
|
Tyagarajan Seshu
Chief Technology Officer
Dirigeant
|
14 322
-12.9%
7,23
103 476 USD
|
14 322
-12.9%
|
7,23
|
103 476 USD
|
|
|
2025-01-17 |
2025-01-15 |
V
Vente
|
Schoch Charles
See Remarks
Dirigeant
|
9 511
-18.1%
7,23
68 717 USD
|
9 511
-18.1%
|
7,23
|
68 717 USD
|
|
|
2025-01-17 |
2025-01-15 |
V
Vente
|
Tak Paul Peter
Chief Executive Officer
Administrateur exécutif
|
21 704
-7.9%
7,23
156 811 USD
|
21 704
-7.9%
|
7,23
|
156 811 USD
|
|
|
2025-01-17 |
2025-01-15 |
V
Vente
|
Barone Francesca
Chief Scientific Officer
Dirigeant
|
13 534
-10.9%
7,23
97 783 USD
|
13 534
-10.9%
|
7,23
|
97 783 USD
|
|
|
2025-01-17 |
2025-01-15 |
V
Vente
|
Nichols William Garrett
Chief Medical Officer
Dirigeant
|
10 428
-11.6%
7,23
75 342 USD
|
10 428
-11.6%
|
7,23
|
75 342 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Tak Paul Peter
Chief Executive Officer
Administrateur exécutif
|
21 172
-7.2%
8,22
173 996 USD
|
21 172
-7.2%
|
8,22
|
173 996 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Schoch Charles
See Remarks
Dirigeant
|
9 971
-15.9%
8,22
81 944 USD
|
9 971
-15.9%
|
8,22
|
81 944 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Barone Francesca
Chief Scientific Officer
Dirigeant
|
13 673
-9.9%
8,22
112 367 USD
|
13 673
-9.9%
|
8,22
|
112 367 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Tyagarajan Seshu
Chief Technology Officer
Dirigeant
|
14 545
-11.6%
8,22
119 534 USD
|
14 545
-11.6%
|
8,22
|
119 534 USD
|
|
|
2025-01-10 |
2025-01-08 |
V
Vente
|
Nichols William Garrett
Chief Medical Officer
Dirigeant
|
10 799
-10.7%
8,22
88 749 USD
|
10 799
-10.7%
|
8,22
|
88 749 USD
|
|
|
2024-12-18 |
2024-12-16 |
A
Achat
|
Manning Paul B
Administrateur non-exécutif
|
750 000
+135.4%
6,00
4 500 000 USD
|
750 000
+135.4%
|
6,00
|
4 500 000 USD
|
|
|
2024-12-18 |
2024-12-16 |
A
Achat
|
Manning Paul B
Administrateur non-exécutif
|
500 000
+77.8%
6,00
3 000 000 USD
|
500 000
+77.8%
|
6,00
|
3 000 000 USD
|
|
|
2024-12-03 |
2024-11-29 |
V
Vente
|
Barone Francesca
Chief Scientific Officer
Dirigeant
|
22 081
-13.8%
4,56
100 592 USD
|
22 081
-13.8%
|
4,56
|
100 592 USD
|
|
|
2024-12-03 |
2024-11-29 |
V
Vente
|
Nichols William Garrett
Chief Medical Officer
Dirigeant
|
13 935
-12.2%
4,56
63 482 USD
|
13 935
-12.2%
|
4,56
|
63 482 USD
|
|
